NCT03009058 - Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

August 30, 2017

Study Completion Date

August 30, 2017

Conditions

Metastatic Cancer

Interventions

BIOLOGICAL

IMM-101

A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365

DRUG

Gemcitabine

Standard of Care chemotherapy

DRUG

Nab-paclitaxel

Standard of Care chemotherapy

DRUG

Capecitabine

Standard of Care chemotherapy

DRUG

Folinic Acid

Standard of Care chemotherapy

DRUG

Fluorouracil

Standard of Care chemotherapy

DRUG

Irinotecan

Standard of Care chemotherapy

DRUG

Oxaliplatin

Standard of Care chemotherapy

BIOLOGICAL

cetuximab

Standard of Care immunotherapy

BIOLOGICAL

Anti-PD1

Standard of Care immunotherapy

BIOLOGICAL

Ipilimumab

Standard of Care immunotherapy

DRUG

Cyclophosphamide

Standard of Care chemotherapy

Trial Locations (4)

69373

Centre Léon Bérard, Dpt Medecine & INSERM, Lyon

94805

Gustave Roussy Cancer Center, Villejuif

SW17 0RE

St George's University of London, Institute of Infection and Immunity, London

SW3 6JJ

Royal Marsden Hospital Foundation Trust, London